Neuland Laboratories Ltd
NEULANDLABNeuland Laboratories Ltd
NEULANDLAB
Price Chart
Scorecard
Performance
HighThe creamy layer - amongst the top performing stocks
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 62.86 | 13.71 | 0.10% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.72 | 6.72 | 0.52% |
Forecast & Ratings
Detailed Forecast from 2 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Neuland Laboratories Limited is engaged in manufacturing active pharmaceutical ingredient (API). The Company also provides custom manufacturing solutions (CMS) to develop and manufacture pharmaceutical ingredients and intermediates.
Investor Presentation
View olderPeers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Torrent Pharmaceuticals Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 511.75 | 580.06 | 531.94 | 670.32 | 766.60 | 953.01 | 953.16 | 1,200.95 | 1,571.12 | 1,565.51 | ||||||||||
Raw Materials | 259.57 | 272.33 | 283.36 | 363.03 | 394.41 | 443.04 | 441.79 | 491.98 | 636.49 | 1,114.51 | ||||||||||
| Power & Fuel Cost | 22.24 | 25.78 | 25.95 | 26.81 | 32.75 | 39.21 | 42.21 | 48.62 | 48.72 | |||||||||||
| Employee Cost | 65.38 | 92.74 | 102.99 | 110.46 | 123.56 | 149.74 | 182.47 | 201.79 | 257.06 | |||||||||||
| Selling & Administrative Expenses | 51.81 | 39.45 | 47.35 | 46.15 | 46.42 | 73.93 | 63.21 | 80.80 | 94.84 | |||||||||||
| Operating & Other expenses | 30.53 | 42.25 | 17.33 | 62.01 | 63.68 | 84.17 | 78.78 | 96.16 | 58.89 | |||||||||||
EBITDA | 82.22 | 107.51 | 54.96 | 61.86 | 105.78 | 162.92 | 144.70 | 281.60 | 475.12 | 451.00 | ||||||||||
| Depreciation/Amortization | 15.74 | 19.23 | 22.10 | 25.86 | 31.28 | 39.68 | 49.04 | 52.78 | 59.70 | 63.95 | ||||||||||
| PBIT | 66.48 | 88.28 | 32.86 | 36.00 | 74.50 | 123.24 | 95.66 | 228.82 | 415.42 | 387.05 | ||||||||||
| Interest & Other Items | 24.48 | 21.09 | 18.93 | 15.66 | 21.57 | 17.90 | 13.50 | 13.07 | 14.00 | 11.08 | ||||||||||
| PBT | 42.00 | 67.19 | 13.93 | 20.34 | 52.93 | 105.34 | 82.16 | 215.75 | 401.42 | 375.97 | ||||||||||
| Taxes & Other Items | 14.68 | 20.32 | 1.87 | 3.90 | 36.72 | 24.71 | 18.34 | 52.23 | 101.36 | 96.28 | ||||||||||
| Net Income | 27.32 | 46.87 | 12.06 | 16.44 | 16.21 | 80.63 | 63.82 | 163.52 | 300.06 | 279.69 | ||||||||||
| EPS | 30.40 | 52.25 | 13.47 | 15.04 | 12.60 | 62.85 | 49.74 | 127.45 | 233.88 | 218.00 | ||||||||||
| DPS | 2.00 | 0.00 | 0.00 | 0.00 | 2.00 | 5.00 | 5.00 | 10.00 | 14.00 | 14.00 | ||||||||||
| Payout ratio | 0.07 | 0.00 | 0.00 | 0.00 | 0.16 | 0.08 | 0.10 | 0.08 | 0.06 | 0.06 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFInvestor Presentation
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Neuland Laboratories Ltd | 58.59 | 13.71 | 0.10% |
| Sun Pharmaceutical Industries Ltd | 46.63 | 6.65 | 0.73% |
| Cipla Ltd | 29.52 | 4.54 | 0.86% |
| Mankind Pharma Ltd | 61.94 | 12.37 | — |
Price Comparison
Compare NEULANDLAB with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Neuland Laboratories Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
HSBC Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 2.7858% | Percentage of the fund’s portfolio invested in the stock 2.84% | Change in the portfolio weight of the stock over the last 3 months 0.63% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 56/109 (0) |
HSBC Multi Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.5218% | Percentage of the fund’s portfolio invested in the stock 2.10% | Change in the portfolio weight of the stock over the last 3 months 0.66% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 59/111 (+8) |
JM Flexicap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.3369% | Percentage of the fund’s portfolio invested in the stock 1.18% | Change in the portfolio weight of the stock over the last 3 months 1.18% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 55/79 (+21) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividend Cuts
NEULANDLAB has increased or maintained dividend levels over the last 5 years
Dividend Yield
Current dividend yield is 0.10%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.04 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJul 12, 2024
Dividend/Share
₹14.00
Ex DateEx Date
Jul 12, 2024
Cash Dividend
Ex DateEx DateJul 11, 2023
Dividend/Share
₹10.00
Ex DateEx Date
Jul 11, 2023
Cash Dividend
Ex DateEx DateJul 14, 2022
Dividend/Share
₹5.00
Ex DateEx Date
Jul 14, 2022
Cash Dividend
Ex DateEx DateJun 29, 2021
Dividend/Share
₹3.00
Ex DateEx Date
Jun 29, 2021
Cash Dividend
Ex DateEx DateNov 10, 2020
Dividend/Share
₹2.00
Ex DateEx Date
Nov 10, 2020
Hindustan Zinc Ltd, Five-Star Business Finance Ltd, Great Eastern Shipping Company Ltd and Triveni Engineering and Industries Ltd are among the other losers in the BSE's 'A' group today, 06 November 2024.Neuland Laboratories Ltd tumbled 13.87% to Rs 13640.05 at 14:47 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 9892 shares were traded on the counter so far as against the average daily volumes of 2786 shares in the past one month.Hindustan Zinc Ltd lost 7.95% to Rs 514.95. The stock was the second biggest loser in 'A' group.On the BSE, 3.55 lakh shares were traded on the counter so far as against the average daily volumes of 1.69 lakh shares in the past one month.Five-Star Business Finance Ltd crashed 2.98% to Rs 653.55. The stock was the third biggest loser in 'A' group.On the BSE, 1.07 lakh shares were traded on the counter so far as against the average daily volumes of 1.29 lakh shares in the past one month.Great Eastern Shipping Company Ltd pared 2.77% to Rs 1258.15. The stock was the fourth biggest loser in 'A' group.On the BSE, 26481 shares were traded on the counter so far as against the average daily volumes of 24976 shares in the past one month.Triveni Engineering and Industries Ltd corrected 2.67% to Rs 406.1. The stock was the fifth biggest loser in 'A' group.On the BSE, 1.09 lakh shares were traded on the counter so far as against the average daily volumes of 33243 shares in the past one month.Powered by Capital Market - Live
Net profit of Neuland Laboratories declined 63.20% to Rs 32.84 crore in the quarter ended September 2024 as against Rs 89.25 crore during the previous quarter ended September 2023. Sales declined 25.59% to Rs 310.84 crore in the quarter ended September 2024 as against Rs 417.75 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales310.84417.75 -26 OPM %20.0232.91 - PBDT65.50136.10 -52 PBT49.42121.59 -59 NP32.8489.25 -63 Powered by Capital Market - Live
Neuland Laboratories will hold a meeting of the Board of Directors of the Company on 6 November 2024.Powered by Capital Market - Live
This Mukul Agrawal-owned stock crossed Rs 10,000-mark; up 725% in 2 years
Neuland Laboratories consolidated net profit rises 58.16% in the June 2024 quarter
Net profit of Neuland Laboratories rose 58.16% to Rs 97.87 crore in the quarter ended June 2024 as against Rs 61.88 crore during the previous quarter ended June 2023. Sales rose 21.11% to Rs 439.60 crore in the quarter ended June 2024 as against Rs 362.99 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales439.60362.99 21 OPM %28.0626.70 - PBDT125.4996.75 30 PBT109.2183.16 31 NP97.8761.88 58 Powered by Capital Market - Live
Stock Alert: Coal India, Bank of Baroda, Tata Steel, Sonata Software, Aster DM Healthcare
Neuland Laboratories will hold a meeting of the Board of Directors of the Company on 1 August 2024.Powered by Capital Market - Live
Goldman Sachs Advises Shareholders To Sell And Buy Their Stakes In These Firms - News18
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 18.57%, vs industry avg of 9.04%
Increasing Market Share
Over the last 5 years, market share increased from 0.31% to 0.42%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 78.76%, vs industry avg of 15.28%